Form 4: HCW Biologics CFO Rebecca Byam Reports Transaction in Company Stock

Rebecca Byam, CFO of HCW Biologics Inc., reports acquisition and disposal of company stock and warrants related to a secured notes conversion.

Summary

• On May 8, 2025, Rebecca Byam, the Chief Financial Officer of HCW Biologics Inc., reported a transaction involving the company's common stock.
• Byam acquired 8,462 shares of common stock at $26 per share.
• Byam also disposed of 43,010 shares.
• Following the reported transactions, Byam beneficially owns 43,010 shares.
• Additionally, Byam acquired 4,231 common stock purchase warrants with an exercise price of $26.
• These transactions are related to a definitive conversion agreement entered into on May 1, 2025, with a conversion date of May 7, 2025.
• The agreement involves the conversion of $6.6 million of secured notes into 253,083 shares of common stock and the issuance of 126,540 warrants.
• The warrants are exercisable for one share of common stock at an exercise price of $26 per share and expire on May 7, 2030.

Sentiment

Score: 6

Explanation: The sentiment is neutral as the filing simply reports transactions related to a previously announced conversion agreement. There's no indication of positive or negative performance, just standard insider activity.

Industry Context

Form 4 filings are standard disclosures required by the SEC to provide transparency into the transactions of company insiders, allowing investors to monitor potential alignment of interests between management and shareholders.

Stakeholder Impact

• Shareholders may be interested in the insider's transactions as it reflects management's actions related to company stock.
• The conversion of secured notes impacts the capital structure of the company.

Key Dates

Keywords

HCW Biologics, Rebecca Byam, CFO, Form 4, Stock Transaction, Common Stock, Warrants, Secured Notes, Conversion Agreement